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Five year follow-up in patients with completely resected stage I 
non-small cell lung cancer following adjuvant chemotherapy with 
UFT
Haam, Seokjin1 Paik, Hyo-Chae1 Kim, Do-Hyung2 Lee, Doo-Yun1 
1 Yongdong Severance Hospital, Yonsei University College of Medicine, 
Seoul, Korea 2 Eulji Hospital, Eulji University College of Medicine, 
Dae-jun, Korea 
Background: Adjuvant treatment following curative resection in stage 
I NSCLC has some controversies, and only a few randomized studies 
have been reported advocating adjuvant UFT chemotherapy for early-
stage NSCLC patients. The purpose of this study was to evaluate the ef-
ﬁcacy of adjuvant UFT chemotherapy in pathological stage I NSCLC.
Methods: We retrospectively studied 86 stage I NSCLC patients who 
underwent complete surgical resection between July 1996 and March 
2002. The patients were randomly assigned to UFT group (n=47, 
surgery and UFT chemotherapy) or control group (n=39, surgery 
alone). Two grams of UFT was administered daily in UFT group for 
21.3±11.7(mean±SD) months.
Results: There were 65 males and 21 females. Mean age at surgery 
was 61.1±10.8 years. Overall mean survival time was 64.9±26.5 
months. Administration of UFT was stopped in 8 patients (17.0%) 
within 12 months due to recurrence in 3 patients, self withdrawal in 3 
patients, and due to severe nausea and poor oral intake in 2 patients. 
The overall 5-year survival rates were 71.9% for the UFT group and 
73.0% for the control group, with no statistically signiﬁcant differ-
ence (p=0.90). In adenocarcinoma patients (N=45), the 5-year survival 
rates were 76.6% for the UFT group (N=26) and 77.1% for the control 
group (N=19), with no statistically signiﬁcant difference (p=0.99). For 
non-adenocarcinoma patients (N=41), the 5-year survival rates were 
66.3% for the UFT group (N=21) and 69.3% for the control group 
(N=20), with no statistically signiﬁcant difference (p=0.82). For stage 
T1 patients (N=36), the 5-year survival rates were 78.3% for the UFT 
group (N=19) and 81.3% for the control group (N=17) with no statisti-
cally signiﬁcant difference (p=0.72). For stage T2 patients (N=50), 
the 5-year survival rates were 67.5% for the UFT group (N=28) and 
67.1% for the control group (N=22), with no statistically signiﬁcant 
difference (p=0.91). The 5-year disease-free survival rates were 65.0% 
for the UFT group and 68.5% for the control group, and there was also 
no statistically signiﬁcant difference (p=0.22). Complications such as 
nausea, general weakness and poor oral intake were noted in 4 patients 
(8.5%) in UFT group.
Conclusions: UFT adjuvant chemotherapy did not increase survival in 
patients with pathologic stage I NSCLC, and prospective randomized 
trial should be applied in the future to draw to a ﬁnal conclusions.
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Prognostic factors in patients with stage IV non-small-cell lung 
cancer
Ma, Meili; Han, Baohui; Jie, Shen; Bai, Hao; Ji, Hao; Zhao, Yizuo; Jin, 
Bo; Yu, Yongfeng; Pei, Jun; Zhang, Wei 
Department of Respiration, Shanghai Chest Hospital, Shanghai, China
Objective: To study incidence of metastasis of stage IV non-small cell 
lung cancer, and analysis prognostic and metastasis organs in non-small 
cell lung cancer (NSCLC) 
Methods: 313 patients with stage IV in NSCLC entered this study 
from 1999.1~2005.4 Three types of data were collected: (1) clinical 
features: generalized status (include sex, age, Kps, typing, pathological 
typing, smoking history, appetite, weight ect): TNM stage (T stage, N 
stage, metastasis).(2) laboratory measurements: HB, LDH, AKP, AST, 
ALT, BUN, CR, albumin: serum tumor marker (CEA, CYFRA211, 
NSE).(3) therapy measure: chemotherapy, the cycle of chemotherapy, 
program, cranial irradiation, bone irradiation, phosphate therapy act. 
Median survival time, overall survival rate, distant metastasis rate were 
the endpoints. Kaplan-Meier method was used for university analysis 
and Cox proportional hazard regression model was used for multivari-
ate analysis. 
Results: 218 and 95 patients metastases to single and different organ 
among the 313 cases of non-small cell (NSCLC) at stage IV. There 
were 63, 174, 127, 3 6, 18, 11, 5 patients with metastasis respectively to 
brain, bone, liver, adrenal gland, subcutaneous and others. The overall 
median survival time for all 313 cases of NSCLC patients was 10.8 
(9.00-12.30) months and the overall 1-,2-,3-,4-and 5-year survival rates 
were 45%, 18%, 12%, 4%, 0%. Kaplan-Meier estimate showed that 
patients anatomic typing, Kps, numbers of metastasis organ, appetite, 
liver, adrenal gland and subcutaneous metastasis, body weight loss, 
smoking, index of smoking, chemotherapy, cycles of chemotherapy 
were the predictors of survival. Multivariate analysis showed statisti-
cally signiﬁcant correlation with anatomic typing, Kps, appetite, liver 
and subcutaneous metastasis, body weight loss, cycles of chemother-
apy. The relative risk (RR) was 1.51, 1.97, 1.55, 1.67, 2.56, and 2.56 
respectively. 
Conclusion: The overall median survival time for all 313 cases of 
NSCLC patients was 10.8 (9.00-12.30) months and the overall 1-,2-
,3-,4-and 5-year survival rates were 45%, 18%, 12%, 4% and 0%. 
Survival time distinctly decreased in patients who had distant metasta-
sis more than two different organs (P<0.01= the median survival time 
was 7.1 months. Bone was the commonest organ to metastatic. The in-
cidence of distant metastasis respectively was 55.59% with bone metas-
tasis 40.58% with lung metastasis 0.13% with brain metastasis 11.50% 
with liver metastasis 5.75% with adrenal gland metastasis, 3.51% with 
subcutaneous metastasis. The survival time was shortest in subcutane-
ous metastasis (4.6 months), and one after another liver 7.0 months, 
brain 8.0 months,adrenal gland 8.6 months, bone 10.6 months, lung 
11.8 months. Cox Multivariate analysis showed liver and subcutaneous 
metastasis, anatomic typing, Kps, appetite, body weight loss, cycles of 
chemotherapy were independent prognostic factors in patient with stage 
IV non-small cell lung cancer.
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Multivariate analysis of factors predictive of brain metastases in 
352 patients with non-small cell lung carcinoma
Han, Baohui1 Bai, Hao2 Shen, Jie2 
1 Shanghai chest hospital, Shanghai, China 2 Shanghai, China 
Objective: This retrospective study attempts to determine the prognos-
tic factors of lung cancer patients with brain metastases and to analysis 
the impact of multi-treatment modalities over survival. We also try 
to investigate the relationship between the expression of P53, nm23, 
VEGF in cancer tissues and the survival of these patients. 
Methods: We reviewed the clinical characteristics of 252 lung cancer 
patients with brain metastases. The multivariate analysis was per-
formed with Cox’s proportion risk model. Treatment modalities include 
